Abiopharma

🔍 HENDERSON MICHAEL THOMAS (Director)

Company: Apogee Therapeutics, Inc. (APGE)

Report Date: 2026-01-14

Detailed Transactions and Holdings:

• Sold 1,440 shares of Common Stock at $78.64 per share (Direct)
  Date: 2026-01-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,211,547.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 8,476 shares of Common Stock at $79.82 per share (Direct)
  Date: 2026-01-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,203,071.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 2,374 shares of Common Stock at $81.0 per share (Direct)
  Date: 2026-01-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,200,697.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 1,854 shares of Common Stock at $82.41 per share (Direct)
  Date: 2026-01-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,198,843.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 5,386 shares of Common Stock at $83.16 per share (Direct)
  Date: 2026-01-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,193,457.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 470 shares of Common Stock at $83.79 per share (Direct)
  Date: 2026-01-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,192,987.00 | transaction_form_type: 4 | Footnotes: F1, F7

Footnotes:

• F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
• F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.16 to $79.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
• F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $79.28 to $80.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.69 to $81.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.70 to $82.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.71 to $83.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.73 to $83.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.